Background: Concurrent chemoradiotherapy is a valuable treatment option for localised
oesophageal cancer (EC), but improvement is still needed. A randomised phase II trial was …

This dose escalation study was designed to determine the maximum tolerated dose (MTD)
and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin …

Background Definitive chemoradiotherapy is a curative treatment option for oesophageal
carcinoma, especially in patients unsuitable for surgery. The PRODIGE5/ACCORD17 trial …

Background Chemoradiation therapy using regimens containing cisplatin and 5-fluorouracil
are most commonly used for inoperable cancer of the esophagus. Cisplatin is relatively toxic …

Aims Although cisplatin–fluoropyrimidine-based definitive chemoradiotherapy (dCRT) is a
standard of care for oesophageal cancer, toxicity is significant and limits its use in elderly …

LBA4003 Background: CRT is one of the best treatment options for localized EC. As new
combinations are required to improve safety and survival, we launched a randomized phase …

This study was performed to assess the efficacy and safety of docetaxel, cisplatin and
fluorouracil combination in patients with unresectable locally advanced oesophageal …

AIMS: A retrospective analysis was carried out of 291 cases of oesophageal cancer treated
with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and …

4530 Background: The aim of this study was to compare survival in a randomized phase III
trial of chemoradiotherapy (CHRT) versus surgery alone for localized resectable …

The locoregional failure rate remains high after concurrent chemoradiotherapy with standard-
dose radiotherapy (RT, 50–50.4 Gy) for oesophageal cancer (EC). This retrospective study …